Phase I study of GRN1005 in recurrent malignant glioma.
CONCLUSION: GRN1005 delivers paclitaxel across the BBB and achieves therapeutic concentrations in tumor tissue. It has similar toxicity to paclitaxel and appears to have activity in recurrent glioma. The recommended phase II dose is 650 mg/m2 every 3 weeks.
PMID: 23349317 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
